Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | TACR1 | P25103 | 6/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14125272 | 1.00 | TSHR (0.48) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL4088276 | 0.93 | TSHR (0.52) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL10581265 | 0.82 | TSHR (0.48) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL9845277 | 0.82 | TSHR (0.48) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL4535810 | 0.79 | TSHR (0.58) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL9747874 | 0.79 | PLA2G10 (0.47) | — | |
| SCHEMBL8374297 | 0.79 | TSHR (0.48) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL10475492 | 0.79 | TSHR (0.48) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL8376718 | 0.79 | TSHR (0.48) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL14125262 | 0.78 | ALDH1A1 (0.51) | CA1CA2CA7CA9SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040102462-A1 | 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative | NESTOR JOHN J (US) | 2004-05-27 | — | — | US | disclosed |
| US-20020042424-A1 | 2- (2-amino-1, 6-dihydro-6 -oxo-purin-9 -yl) methoxy-1, 3 -propanediol derivative | ROCHE PALO ALTO LLC | 2002-04-11 | — | — | US | disclosed |
| US-6083953-A | Treating herpes simplex virus or cytomegalovirus infections; valganciclovir hydrochloride in crystalline form; antiviral; oral administration | SYNTEX (U.S.A.) INC. (US) | 2000-07-04 | — | — | US | disclosed |
| EP-0694547-B1 | 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivatives | HOFFMANN LA ROCHE (CH) | 1999-04-21 | — | — | EP | disclosed |
| US-5856481-A | Synthesis of antiviral agent valganciclovir (2-(2-amino-1,6-dihydro6-oxo-purin-9-yl)methoxy-3-hydroxy-1-propanyl-L-valinate) or salts via deprotection and salt formation | SYNTEX (U.S.A.) INC. (US) | 1999-01-05 | — | — | US | disclosed |
| US-5840891-A | VIRICIDES WITH IMPROVED ABSORPTION | SYNTEX (U.S.A.) INC. (US) | 1998-11-24 | — | — | US | disclosed |
| US-5543414-A | VIRICIDES | SYNTEX (USA) INC. (US) | 1996-08-06 | — | — | US | disclosed |
| EP-0694547-A2 | 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative | F. Hoffmann-La Roche AG (CH) | 1996-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042424-A1 | 2- (2-amino-1, 6-dihydro-6 -oxo-purin-9 -yl) methoxy-1, 3 -propanediol derivative | DPP7, PURB, EIF2AK2 | TSHR 4834/4885CA1 4809/4885CA2 4527/4885 |
| US-20040102462-A1 | 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative | DPP7, PURB, EIF2AK2 | TSHR 4834/4885CA1 4809/4885CA2 4527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.